Editorial New guidelines for HER2 pathological diagnostics in gastric cancer
|
|
- Norah Cooper
- 5 years ago
- Views:
Transcription
1 bs_bs_banner Pathology International 2016; 66: doi: /pin Editorial New guidelines for HER2 pathological diagnostics in gastric cancer Ryo Wada, 1 Kenichi Hirabayashi, 2 Nobuyuki Ohike 3 and Eiichi Morii 4 1 Department of Pathology, Juntendo University Shizuoka Hospital, Shizuoka, 2 Department of Pathology, Tokai University School of Medicine, 3 Department of Pathology, Showa University Fujigaoka Hospital, Kanagawa and 4 Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan The aim of this editorial is to introduce new guidelines, including novel evidence and figures, on the human epidermal growth factor receptor 2 (HER2) pathological diagnosis of gastric cancer. In breast cancer, HER2 protein overexpression and HER2 gene amplification are significant prognostic factors and are targets for therapy. Therefore, technical methods and criteria for determining HER2 overexpression have been developed. Since these HER2 findings are also important in gastric cancer, the quality control committee of the Japanese Society of Pathology produced guidelines for the pathological diagnosis of HER2 expression in gastric cancer, including methods for pathological analysis. These guidelines were led by Dr. Kijima Hiroshi and were published in November 2011 ( patho2/seidokanri/igan_her2.pdf). The guidelines suggested in this paper were created based on new evidence and include inputs from Dr. Wada Ryo, Dr. Hirabayashi Kenichi, and Dr. Ohike Nobuyuki who were recommended by the guideline s author, Dr. Kijima. New figures are also presented. These guidelines should be referred to for the pathological diagnosis of HER2 in gastric cancer. CLINICAL QUESTION (CQ)-1 What is the major histological subtype for the gastric cancer with HER2 protein overexpression? The rate of HER2 protein over-expression is higher in differentiated gastric adenocarcinomas than in undifferentiated gastric adenocarcinomas. Figure 1 Resected stomach. Hematoxylin and eosin (H&E) staining: moderately differentiated tubular adenocarcinoma (tub2). Immunohistochemistry (IHC) method: strong cell membrane (mainly lateral) positive tumor cells are observed in 10% or more of one section, equivalent to a score of 3 +. An anti-her-2/neu (4B5) rabbit monoclonal primary antibody (Roche Diagnostics, Tokyo, Japan) was used. The same antibody was used for the IHC in Figures 2 6. Dual color in situ hybridization (DISH) method: high amplification is seen, with a HER2/CEP17 ratio of 10.4, which was determined to be positive. R. W., K. H, and N. O. equally contributed to this work. April 2015 edition Edited by the committee of the Japanese Society of Pathology on guidelines for HER2 pathological diagnostics in gastric cancer
2 58 Editorial Figure 2 Resected stomach. Hematoxylin and eosin (H&E) staining: welldifferentiated tubular adenocarcinoma (tub1), intestinal type. Immunohistochemistry (IHC) method: weak cell membrane positive tumor cells are observed in 10% or more of one section, equivalent to a score of 2 +. Dual color in situ hybridization (DISH) method: mild amplification is seen, with a HER2/CEP17 ratio of 2.9, which was determined to be positive. Figure 3 Stomach biopsy. Hematoxylin and eosin (H&E) staining: poorlydifferentiated adenocarcinoma (por1). Immunohistochemistry (IHC) method: weak to moderate cell membrane positive tumor cell clumps are observed, equivalent to a score of 2 +. Dual color in situ hybridization (DISH) method: no amplification is seen, with a HER2/CEP17 ratio of 1.4, which was determined to be negative. Figure 4 Stomach biopsy. Hematoxylin and eosin (H&E) staining: poorly differentiated adenocarcinoma (por2). Immunohistochemistry (IHC) method: weak to moderate cell membrane positive tumor cell clumps are observed, equivalent to a score of 2 +. Dual color in situ hybridization (DISH) method: mild amplification is seen, with a HER2/CEP17 ratio of 3.2, which was determined to be positive. Outline of the evidence: HER2 overexpression in gastric cancer varies with tumor type. Fifteen to 50% of intestinal type gastric cancers overexpress HER2, whereas approximately 2 25% of diffuse/mixed type gastric cancers express HER2 (Figs 1 4). 1 6 All tumor classifications were based on Lauren s criteria. HER2 overexpression in intestinal or well-differentiated gastric carcinomas was associated with a worse prognosis than that of HER2-negative tumors, although there have been no studies on the prognostic differences between HER2 expression in diffuse or mixed types. 3 When several histological types are intermingled in the same materials, there are no criteria outlining which histological type to select for HER2 evaluation. The material including intestinal type may be selected because the rate of HER2 positivity is high in this type.
3 Editorial 59 1 Dang HZ, Yu Y, Jiao SC. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol 2012; 18: Fan XS, Chen JY, Li CF et al. Differences in HER2 overexpression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol 2013; 19: He C, Bian XY, Ni XZ et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013; 19: Kim KC, Koh YW, Chang HM et al. Evaluation of HER2 protein expression in gastric carcinomas: Comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18: Liang JW, Zhang JJ, Zhang T, Zheng ZC. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: A meta-analysis of the literature. Tumour Biol 2014; 35: Oh HS, Eom DW, Kang GH et al. Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer 2014; 17: (the date of investigation). CQ-2 To what degree is the rate of the HER2 expression heterogenicity in gastric cancer due to HER2 protein overexpression? The incidence of HER2 expression heterogenicity in gastric cancers examined for HER2 protein overexpression has been reported to be 20 80%. Outline of evidence: HER2 expression heterogenicity is higher in gastric cancer than in breast cancer. HER2 heterogenicity is observed in approximately 45 79% of gastric cancers by immunohistochemistry (IHC) and in approximately 23 54% by in situ hybridization (ISH; fluorescence ISH, FISH). Heterogeneity tends to be detected better in IHC than in FISH (Fig. 5). 1 4 In particular, HER2 heterogenicity has been well observed in diffuse/mixed type cancers, score 2 HER2 cases by IHC, and low-level amplification cases by FISH. 2 When HER2 overexpression is limited to the intramucosal carcinoma lesion within the surgically resected material, the pathological details of this staining finding may be recorded. The pathological diagnosis of intramucosal gastric neoplasia differs between Japan and Western countries, and the ToGA test was based on the diagnosis in Western countries. This is why the description of HER2 expression in intramucosal lesions is recommended Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59: Lee HE, Park KU, Yoo SB et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013; 49: Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: Issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59: Yang J, Luo H, Li Y et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys 2012; 62: Wada R, Abe H, Taki K, Kuwabara N. Immunohistochemical expression of c-myc oncogene products, c-erbb-2 gene product, protein kinase c and lysozyme in gastric super minute tubular adenocarcinomas (measuring up to 1 mm in diameter). Acta Histochem Cytochem 1991; 24: Yoshida H, Yamamoto N, Taniguchi H et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch 2014; 465: Fusco N, Rocco EG, Del Conte C et al. HER2 in gastric cancer: A digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol 2013; 26: Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: Fassan M, Mastracci L, Grillo F et al. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012; 61: Valente P, Garrido M, Gullo I et al. Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggresiveness. Gastric Cancer 2015; 18: Boku N. HER2-positive gastric cancer. Gastric Cancer 2014; 17: (the date of investigation), except reference no. 5. CQ-3 To what degree is HER2 protein overexpression concordant between primary and metastatic gastric cancer lesions? The rate of HER2 overexpression concordance between primary and metastatic carcinomatous lesions in gastric cancer is more than 80%. Outline of the evidence: The concordance of HER2 expression between primary and metastatic carcinomatous lesions in gastric cancer is approximately % when measured by ISH (FISH; dual color in situ hybridization, DISH) and approximately 80 95% when measured by IHC. 1 4 Heterogeneity of HER2 expres-
4 60 Editorial Figure 5 Resected stomach. Left upper: Immunohistochemistry (IHC) method: intratumoral heterogeneity of HER2 expression. Left lower: IHC method: strong near-circumferential cell membrane positive cells, equivalent to a score of 3 +. Dual color in situ hybridization (DISH) method: high amplification is seen, with a HER2/CEP17 ratio of 11.5, which was determined to be positive. Right upper: IHC method: no positive cells are seen in the tumor cells, equivalent to a score of 0. Dual color in situ hybridization (DISH) method: no amplification is seen, with a HER2/CEP17 ratio of <2.0, which was determined to be negative. sion in primary lesions is observed in cases of nonconcordance between HER2 expression in primary and metastatic tumors (Fig. 6). If HER2 expression heterogeneity exists in the primary lesion, then there is a possibility for non-concordance among metastatic lesions. Currently, there is no evidence on the effectiveness of anti-her2 therapy in cases where HER2 is differentially expressed in primary and metastatic lesions. 3 Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59: Kochi M, Fujii M, Masuda S et al. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol 2013; 8: 191. (the date of investigation). 1 Bozzetti C, Negri FV, Lagrasta CA et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104: Fassan M, Ludwig K, Pizzi M et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol 2012; 43: CQ-4 To what degree is the rate of HER2 overexpression concordant between biopsy and surgically resected specimens in gastric cancer?
5 Editorial 61 Figure 6 Gastric cancer with bone metastasis. Upper (resected stomach) (8-year-old material): Hematoxylin and eosin (H&E) staining: poorly-differentiated adenocarcinoma (por2). Immunohistochemistry (IHC) method: no positive tumor cells are observed, equivalent to a score of 0. Dual color in situ hybridization (DISH) method: unable to evaluate due to inadequate CEP17 staining. Lower (bone biopsy): H&E staining: metastatic adenocarcinoma. IHC method: strong near-circumferential cell membrane positive tumor cells are observed in 10% or more of one section, equivalent to a score of 3 +. DISH method: high amplification is seen, with a HER2/CEP17 ratio of 15.6, which was determined to be positive. The concordance rate of HER2 protein overexpression between biopsy and surgically resected gastric cancer specimens in gastric cancer is over 60%. Outline of the evidence: The concordance rate of HER2 expression between biopsy specimens and surgically resected specimens is 57 89% by IHC and 62 96% by ISH (FISH/DISH), there are no significant differences between IHC and ISH. 1 4 Yoshida et al. 4 reported that the concordance rates of HER2 expression between biopsy and surgically resected material were K = by IHC and K = by FISH. Using both IHC and ISH, the concordance rate of HER2 expression between biopsy specimens and surgically resected specimens is approximately 92 96%. 1,5 Lee et al. 2 reported that the relatively high concordance of HER2 expression between biopsy and surgically resected specimens was observed in score 0 (70%, 28/40 cases) and score 3 samples (71%, 5/7 cases), whereas there was no concordance in score 1(3 cases) or score 2 (4 cases) samples. The rate of HER2 expression concordance between biopsy and surgically resected specimens showed lower heterogeneity in surgically resected materials (24% vs. 80%, P = 0.016). 5 Although there are no clear criteria regarding how many samples should be taken during biopsy, there are no significant differences between the number of samples taken by biopsy and concordance (5.6 vs. 5.8, P = 0.83). 5 1 Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci 2013; 58:
6 62 Editorial 2 Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: Issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59: Yano T, Doi T, Ohtsu A et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: Yoshida H, Yamamoto N, Taniguchi H et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch 2014; 465: Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol 2014; 45: (The date of investigation). (NOTE) DISH METHOD DISH method: the overexpression of HER2 in tumor cells occurs in association with genetic amplification at the DNA level. To observe this amplification, the FISH method is normally used; however, the clinical application of the DISH method, which enables the analysis of DNA in a bright field, is also expected. HER2 genes are labeled with silver particles, and the centromere of chromosome 17 is visualized by a red color. This method of evaluation is the same as that of the FISH method, and a HER2/CEP17 ratio 2.0 is determined to be positive. None declared. DISCLOSURE STATEMENT
Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer
MOLECULAR AND CLINICAL ONCOLOGY 2: 751-755 Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer RYOSUKE SHIBATA 1,
More informationHER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient
Journal of Pathology and Translational Medicine 2017; 51: 396-402 ORIGINAL ARTICLE HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient Dang Anh Thu Phan Vu Thien Nguyen Thi Ngoc
More informationRESEARCH ARTICLE. Fatih Selcukbiricik 1 *, Sibel Erdamar 2, Evin Buyukunal 3, Suheyla Serrdengecti 3, Fuat Demirelli 3. Abstract.
DOI:http://dx.doi.org/10.731/APJCP.201.15.2.10607 RESEARCH ARTICLE Is Her-2 Status in the Primary Tumor Correlated with Matched Lymph Node Metastases in Patients with Gastric Cancer Undergoing Curative
More informationHER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD
HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD Carcinoma of the stomach is the fourth most common cancer and second most frequent cause of cancer-related mortality
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationRESEARCH ARTICLE. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India
DOI:10.22034/APJCP.2018.19.5.1381 RESEARCH ARTICLE Editorial Process: Submission:01/27/2018 Acceptance:03/29/2018 Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North
More informationHER2 status in premalignant dysplastic gastric lesions
www.edoriumjournals.com Editorial open ACCESS HER2 status in premalignant dysplastic gastric lesions Valeria Barresi, Antonio Ieni, Giovanni Tuccari ABSTRACT Abstract is not required for Editorial International
More informationMinimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
THIEME Original article Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer Authors Institutions Irene Gullo 1, *, Federica Grillo 1, *, Luca Molinaro 2, Matteo Fassan
More informationAuthor s response to reviews
Author s response to reviews Title: Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections Authors: Renato Santos Laboissiere
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationHER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma
IJMCM Autumn 203, Vol 2, No 4 Original Article HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma Kourosh Movagharnejad, Majid Sharbatdaran,
More informationONCOLOGY LETTERS 5: , 2013
ONCOLOGY LETTERS 5: 559-563, 2013 The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel GIL BAR-SELA
More informationIdeal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
/, Vol. 6, No. 35 Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens Sangjeong Ahn 1,6,*, Soomin Ahn 1,2,*, Michael Van Vrancken 1,*, Minju Lee 1,
More informationIncidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma.
Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Christophe Blay, Dan Cristian Chiforeanu, Eveline Boucher, Florian Cabillic, Romain Desgrippes, Bérengère Leconte,
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationCorrelation of Lauren s histological type and expression of E-cadherin and HER-2/ neu in gastric adenocarcinoma
IJPLM. 2016;2(1):OA2 ORIGINAL ARTICLES Correlation of Lauren s histological type and expression of E-cadherin and HER-2/ neu in gastric adenocarcinoma Khushboo Dewan 1*, Renu Madan 2, P Sengupta 3 1, 2,
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationKey words: gastric cancer, tumor location, pathology, outcome
JBUON 2019; 24(2): 650-655 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Addition of taxanes to combination chemotherapy in distal intestinal
More informationIt s not a four legged animal anymore. Disclosure
It s not a four legged animal anymore Parminder Singh, MD Assistant Professor of Medicine Division hematology and oncology No disclosures Disclosure 1 Four legged animal which use the tips of their toes,
More informationImmunohistochemical Expression of Her2/neu in Gastric Carcinomas in Egyptian Patients
Research Article imedpub Journals www.imedpub.com Journal of Clinical Pathology and Diagnosis Abstract Immunohistochemical Expression of Her2/neu in Gastric Carcinomas in Egyptian Patients Background:
More informationPrimary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings
CASE REPORT Primary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings Makoto Nagashima 1, Ayako Moriyama 1, Yasuo
More informationDiscordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma
Original Article Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma Ellie Chan 1, Lizette Vila Duckworth 2, Ahmad Alkhasawneh 2, Tania Zuluaga Toro
More informationResident Short Review. HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma
Resident Short Review HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma A Review of Histopathology, Diagnostic Testing, and Clinical Implications
More informationKey words: epidermal growth factor receptor, c-erbb-2, esophageal cancer, gastric cancer, colonic cancer
Key words: epidermal growth factor receptor, c-erbb-2, esophageal cancer, gastric cancer, colonic cancer Table 1 Histologic types of esophageal, gastric and colonic cancer and human gastric cancer xenografts
More informationHER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer Yanjun Hou, MD, PhD, 1 Hiroaki Nitta, PhD, 2 and Zaibo Li, MD, PhD 1 From the
More informationHuman Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
More informationMET-Amplified Intramucosal Gastric Cancer Widely Metastatic after Complete Endoscopic Submucosal Dissection
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2014 Aug 25 [Epub ahead of print] Case Report http://dx.doi.org/10.4143/crt.2013.137 Open Access MET-Amplified Intramucosal Gastric Cancer Widely Metastatic
More informationc-erbb-2 expression and prognosis of gastric cancer: a meta-analysis
c-erbb-2 expression and prognosis of gastric cancer: a meta-analysis Z.Q. Wang and B.J. Sun Department of Surgery, Affiliated Tongren Hospital, Shanghai Jiaotong University, Shanghai, China Corresponding
More informationOriginal article. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous
Original article A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein over-expression and gene-amplification reveal intratumoral heterogeneity
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationCase Report Intramucosal Signet Ring Cell Gastric Cancer Diagnosed 15 Months after the Initial Endoscopic Examination
Hindawi Publishing Corporation Case Reports in Medicine Volume 2015, Article ID 479625, 5 pages http://dx.doi.org/10.1155/2015/479625 Case Report Intramucosal Signet Ring Cell Gastric Cancer Diagnosed
More informationUpdate on Published CAP/ASCP/ASCOHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
8001-17 Update on Published CAP/ASCP/ASCOHER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Kay Washington, MD, PhD Vanderbilt University Medical Center DISCLOSURE In the past
More informationOriginal Article. Jennifer Jeung, MD; Roshan Patel, MD; Lizette Vila, MD; Dara Wakefield, MD; Chen Liu, MD, PhD
Original Article Quantitation of HER2/neu Expression in Primary Gastroesophageal Adenocarcinomas Using Conventional Light Microscopy and Quantitative Image Analysis Jennifer Jeung, MD; Roshan Patel, MD;
More informationImportance of confirming HER2 overexpression of recurrence lesion in breast cancer patients
Breast Cancer (2013) 20:336 341 DOI 10.1007/s12282-012-0341-6 ORIGINAL ARTICLE Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients Rikiya Nakamura Naohito Yamamoto
More informationDetection and Clinical Significance of Lymph Node Micrometastasis in Gastric Cardia Adenocarcinoma
The Journal of International Medical Research 2012; 40: 293 299 [first published online ahead of print as 40(1) 3] Detection and Clinical Significance of Lymph Node Micrometastasis in Gastric Cardia Adenocarcinoma
More informationVersion 2 of these Guidelines were drafted in response to published updated ASCO/CAP HER2 test Guideline Recommendations-
Introduction: These guidelines represent systematically developed statements to assist in the provision of quality assured HER2 testing in breast and gastric/ gastro-oesophageal carcinoma. They are based
More informationGastric Adenocarcinoma: Study of the Immunophenotypic Profile in View of the Latest Molecular Knowledge on Carcinogenesis
Human Journals Research Article March 2018 Vol.:11, Issue:4 All rights are reserved by Stefania Erra et al. Gastric Adenocarcinoma: Study of the Immunophenotypic Profile in View of the Latest Molecular
More informationHER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
ONCOLOGY LETTERS 6: 13-18, 2013 HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma JUN XING HUANG 1, KUN ZHAO 1, MEI LIN
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationSystematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience
Woo et al. Diagnostic Pathology (2016) 11:102 DOI 10.1186/s13000-016-0553-8 RESEARCH Open Access Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience Jennifer S. Woo
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #450 (NQF 1858): Trastuzumab Received By Patients With AJCC Stage I (T1c) III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy National Quality Strategy Domain: Effective Clinical
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationUpper GIT IV Gastric cancer
Upper GIT IV Gastric cancer Luigi Tornillo PathoBasic 23.10.2014 Pathology Introduction Classification Morphogenesis Problems Intraepithelial neoplasia Surveillance EGJ Predictive factors Gastric cancer
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationEsophageal seeding after endoscopic ultrasound-guided fine-needle aspiration of a mediastinal tumor
Esophageal seeding after endoscopic ultrasound-guided fine-needle aspiration of a mediastinal tumor Authors Kensuke Yokoyama 1,JunUshio 1,NorikatsuNumao 1, Kiichi Tamada 1, Noriyoshi Fukushima 2, Alan
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationA case of different EGFR mutations in surgically resected synchronous triple lung cancer
Case Report A case of different EGFR mutations in surgically resected synchronous triple lung cancer Naoki Haratake 1, Mitsuhiro Takenoyama 1, Makoto Edagawa 1, Shinichiro Shimamatsu 1, Ryo Toyozawa 1,
More informationClinicopathological and prognostic differences between mucinous gastric carcinoma and signet-ring cell carcinoma
Original Article Clinicopathological and prognostic differences between mucinous gastric carcinoma and signet-ring cell carcinoma Zhaode Bu, Zhixue Zheng, Ziyu Li, Xiaojiang Wu, Lianhai Zhang, Aiwen Wu,
More informationTargeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example
Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationCHAPTER 7 Concluding remarks and implications for further research
CONCLUDING REMARKS AND IMPLICATIONS FOR FURTHER RESEARCH CHAPTER 7 Concluding remarks and implications for further research 111 CHAPTER 7 Molecular staging of large sessile rectal tumors In this thesis,
More informationAssociation between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
Laboissiere et al. BMC Gastroenterology (2015) 15:157 DOI 10.1186/s12876-015-0384-1 RESEARCH ARTICLE Open Access Association between HER2 status in gastric cancer and clinicopathological features: a retrospective
More informationImmunohistochemical consistency between primary tumors and lymph node metastases of gastric neuroendocrine carcinoma
Uchiyama et al. World Journal of Surgical Oncology 2012, 10:115 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Immunohistochemical consistency between primary tumors and lymph node metastases
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationEvaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters
Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters Mehdi Farzadnia, Naser TayyebiMeibodi, Fatemeh HomayiShandiz,
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationHER2 Testing of Multifocal Invasive Breast Carcinoma. Gillian C. Bethune, MD, J. Brendan Mullen, MD, and Martin C. Chang, MD, PhD
HER2 Testing of Multifocal Invasive Breast Carcinoma How Many Blocks Are Enough? Gillian C. Bethune, MD, J. Brendan Mullen, MD, and Martin C. Chang, MD, PhD From the Department of Pathology and Laboratory
More informationHER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value conclusions from 924 cases of two independent series
Cellular Oncology 32 (2010) 57 65 57 DOI 10.3233/CLO-2009-0497 IOS Press HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value conclusions from 924 cases of two independent
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationHistopathology of Endoscopic Resection Specimens from Barrett's Esophagus
Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus Br J Surg 38 oct. 1950 Definition of Barrett's esophagus A change in the esophageal epithelium of any length that can be recognized
More informationThe detection rate of early gastric cancer has been increasing owing to advances in
Focused Issue of This Month Sung Hoon Noh, MD, ph.d Department of Surgery, Yonsei University College of Medicine E - mail : sunghoonn@yuhs.ac J Korean Med Assoc 2010; 53(4): 306-310 Abstract The detection
More informationReviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:
Reviewer's report Title: Validation of HER2 testing with core needle biopsy specimens from primary breast cancers in terms of interobserver reproducibility and concordance with surgically resected specimens
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationInternational Journal of Medical Science and Health Research
A Retrospective Study of Clinicopathological Profiles of Proximal Gastrectomy Vs Distal Gastrectomy in Carcinoma Stomach and Its Incidence in our Population Dr Magesh kumar J 1, Dr V Naveen Kumar 2, Dr
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationAssessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray
Assessment of Breast Cancer with Borderline HER2 Status Using MIP Microarray Hui Chen, Aysegul A Sahin, Xinyan Lu, Lei Huo, Rajesh R Singh, Ronald Abraham, Shumaila Virani, Bal Mukund Mishra, Russell Broaddus,
More informationReviews in Clinical Medicine
Mashhad University of Medical Sciences (MUMS) Reviews in Clinical Medicine Clinical Research Development Center Ghaem Hospital Prognostic value of HER2/neu expression in patients with prostate cancer:
More informationSatisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy
Original Article Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy Shupeng Zhang 1, Liangliang Wu 2, Xiaona Wang 2, Xuewei Ding 2, Han Liang 2 1 Department of General
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationESD for EGC with undifferentiated histology
ESD for EGC with undifferentiated histology Jun Haeng Lee, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Biopsy: M/D adenocarcinoma ESD: SRC >>
More informationConventional Gastrectomy for Gastric Cancer. Franklin Wright UCHSC Department of Surgery Grand Rounds January 14, 2008
Conventional Gastrectomy for Gastric Cancer Franklin Wright UCHSC Department of Surgery Grand Rounds January 14, 2008 Overview Gastric Adenocarcinoma Conventional vs Radical Lymphadenectomy Non-randomized
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationExpression of the GLUT1 and p53 Protein in Atypical Mucosal Lesions Obtained from Gastric Biopsy Specimens
The Korean Journal of Pathology 2006; 40: 32-8 Expression of the GLUT1 and p53 Protein in Atypical Mucosal Lesions Obtained from Gastric Biopsy Specimens In Gu Do Youn Wha Kim Yong-Koo Park Department
More informationWhat is HER2 positive breast cancer in 2018? Updated ASCO-CAP guidelines. Giuseppe Viale University of Milan European Institute of Oncology
What is HER2 positive breast cancer in 2018? Updated ASCO-CAP guidelines Giuseppe Viale University of Milan European Institute of Oncology Mission accomplished! First alarming results Breast Intergroup
More information위장관종양의표적치료를위한 면역조직화학적및분자병리학적 진단기법 이혜승 분당서울대학교병원병리과
위장관종양의표적치료를위한 면역조직화학적및분자병리학적 진단기법 이혜승 분당서울대학교병원병리과 Contents HER2 testing in gastric cancer - Clinicopathologic significance of HER2 - Practical approach of HER2 testing Resistance to anti-egfr therapy
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationClinical Usefulness of the WHO Histological Classification of Thymoma
Original Article Clinical Usefulness of the WHO Histological Classification of Thymoma Satoshi Sonobe, MD, 1 Hideaki Miyamoto, MD, 1 Hiroshi Izumi, MD, 2 Bunsei Nobukawa, MD, 2 Toshiro Futagawa, MD, 1
More informationIntratumoral Heterogeneity in Breast Cancer: A Case Report and Molecular Discussion
Original Case Report Article Middle East Journal of Cancer; July October 20152018; 6(3): 9(4): 339-343 Intratumoral Heterogeneity in Breast Cancer: A Case Report and Molecular Discussion Akbar Safaei,
More informationKey Words. Gastric cancer HER-2 Prognosis IHC FISH
The Oncologist Gastrointestinal Cancer Impact of HER-2 Overexpression/Amplification on the Prognosis of Gastric Cancer Patients Undergoing Resection: A Single-Center Study of 1,036 Patients JUN-TE HSU,
More informationMolecular Pathology of Gastric Cancer
Molecular Pathology of Gastric Cancer Novel insights and possible future applications Fátima Carneiro i3s/ipatimup& Medical Faculty/ CHS João Porto, Portugal Outline 1. Major histological types of gastric
More informationHER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy
HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy Shigeya Kyoda 1, Satoki Kinoshita 2, Hiroshi Takeyama 1, Ken Uchida 2 and Toshiaki Morikawa 2 1 Department of Surgery, Jikei
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationMolecular Probes Introducing 14 new probes
Molecular Probes Introducing 14 new probes Gene and Chromosome Probes Dual Colour ISH INFORM HER2 Dual ISH DNA Probe Cocktail Assay Product Part Number INFORM HER2 Dual ISH DNA Probe Cocktail 800-4422
More informationMucinous Adenocarcinoma of the Stomach Clinicopathological
THE KURUME MEDICAL JOURNAL Vo1. 43, p. 289-294, 1996 ORIGINAL ARTICLE Mucinous Adenocarcinoma of the Stomach Clinicopathological Studies KIKUO KOUFUJI, JINRYO TAKEDA, ATSUSHI TOYONAGA, ISSEI KODAMA, KEISHIRO
More informationCASE REPORT. Introduction. Case Report. Kimitoshi Kubo 1, Noriko Kimura 2, Katsuhiro Mabe 1, Yusuke Nishimura 1 and Mototsugu Kato 1
doi: 10.2169/internalmedicine.0842-18 Intern Med 57: 2951-2955, 2018 http://internmed.jp CASE REPORT Synchronous Triple Gastric Cancer Incorporating Mixed Adenocarcinoma and Neuroendocrine Tumor Completely
More informationHow to treat early gastric cancer? Endoscopy
How to treat early gastric cancer? Endoscopy Presented by Pierre H. Deprez Institution Cliniques universitaires Saint-Luc, Brussels Université catholique de Louvain 2 3 4 5 6 Background Diagnostic or therapeutic
More informationStudy of expression of P53 in Gastric Carcinoma As a prognostic indicator
Original Research Article Study of expression of P53 in Gastric Carcinoma As a prognostic indicator K. Padma Malini 1*, Srivani 2, O. Shravan Kumar 3 1 Assistant Professor, 2 Associate Professor, 3 Professor
More informationHER2 Overexpression and Amplification in Urothelial Carcinoma of the Bladder Is Associated With MYC Coamplification in a Subset of Cases
Anatomic Pathology / HER2 and MYC in Urothelial Carcinoma HER2 Overexpression and Amplification in Urothelial Carcinoma of the Bladder Is Associated With MYC Coamplification in a Subset of Cases Donna
More informationCase Report Five-Year Survival after Surgery for Invasive Micropapillary Carcinoma of the Stomach
Case Reports in Surgery Volume 2013, Article ID 560712, 4 pages http://dx.doi.org/10.1155/2013/560712 Case Report Five-Year Survival after Surgery for Invasive Micropapillary Carcinoma of the Stomach Shigeo
More information